Attributes | Values |
---|
rdf:type
| |
rdfs:seeAlso
| |
Description
| - A comparative study performed in 113 iron overloaded patients with early myelodysplastic syndromes showed a substantial decrease in iron stores ( > 50% of intial values) in 27,7% of patients treated with deferasirox in kontrast to none of the patients treated with deferiprone. Incidence of side effects was similar in both the drugs, however side effects related to deferasirox administration were mostly mild and reversible nad allowed to continue drug admnistration after temporary cesation of the treatment. On the contrary deferiprone administration had to be stopped due to side effects in 20% of patients. Deferasirox represents relatively safe first line chelation treatment in MDS patients.
- A comparative study performed in 113 iron overloaded patients with early myelodysplastic syndromes showed a substantial decrease in iron stores ( > 50% of intial values) in 27,7% of patients treated with deferasirox in kontrast to none of the patients treated with deferiprone. Incidence of side effects was similar in both the drugs, however side effects related to deferasirox administration were mostly mild and reversible nad allowed to continue drug admnistration after temporary cesation of the treatment. On the contrary deferiprone administration had to be stopped due to side effects in 20% of patients. Deferasirox represents relatively safe first line chelation treatment in MDS patients. (en)
|
Title
| - A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes
- A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes (en)
|
skos:prefLabel
| - A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes
- A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes (en)
|
skos:notation
| - RIV/00023736:_____/13:00010730!RIV14-MZ0-00023736
|
http://linked.open...avai/predkladatel
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00023736:_____/13:00010730
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - deferasirox; chelation; Deferiprone; myelodysplasia; side effects; toxicity (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Jonášová, A.
- Neuwirtová, R.
- Čermák, Jaroslav
- Vondráková, J.
- Bělohlávková, P.
- Červínek, L.
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| - 10.1016/j.leukres.2013.07.021
|